Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs
Go back to Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs| (NASDAQ: JAGX) | Delayed: 2.61 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.61 | 52 Week High | $4.60 | |||
| Open | $2.61 | 52 Week Low | $0.81 | |||
| Day High | $2.61 | P/E | N/A | |||
| Day Low | $2.61 | EPS | $0.00 | |||
| Volume | 2,643 | |||||
